Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17145407 | 1.00 | SLC6A3 (0.32) | SLC6A3ALDH1A1KDM4EMEN1CYP1A2 | |
| SCHEMBL818821 | 0.74 | TSHR (0.35) | SLC6A3ALDH1A1KDM4ETDP1ATM | |
| SCHEMBL460975 | 0.74 | SLC6A3 (0.32) | SLC6A3 | |
| SCHEMBL461375 | 0.71 | ATM (0.36) | SLC6A3ALDH1A1MEN1KMT2AATM | |
| SCHEMBL17145405 | 0.71 | ATM (0.36) | SLC6A3ALDH1A1MEN1KMT2AATM | |
| SCHEMBL17145406 | 0.69 | PSEN1 (0.34) | SLC6A3KDM4E | |
| SCHEMBL459862 | 0.69 | PSEN1 (0.34) | SLC6A3KDM4E | |
| SCHEMBL459352 | 0.65 | ATM (0.40) | SLC6A3ALDH1A1ATM | |
| SCHEMBL17145432 | 0.65 | ATM (0.40) | SLC6A3ALDH1A1ATM | |
| SCHEMBL819397 | 0.61 | CHRM3 (0.35) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150531-B2 | Tricyclic lactones for treatment of cancer | GLACTONE PHARMA DEVELOPMENT AB (SE) | 2015-10-06 | — | — | US | disclosed |
| EP-2595972-B1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | GLACTONE PHARMA DEV AB (SE) | 2015-08-19 | — | — | EP | disclosed |
| US-20130310451-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | GLACTONE PHARMA DEVELOPMENT AB (SE) | 2013-11-21 | — | — | US | disclosed |
| EP-2595972-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | Glactone Pharma Development AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010555-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | PARTNERS FÖR UTVECKLINGSINVESTERINGAR INOM LIFE SCIENCES, P.U.L.S. AB (SE) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012011864-A1 | BICYCLIC COMPOUNDS AND PROCESS FOR PREPARATION | PARTNERS FÖR UTVECKLINGSINVESTERINGAR INOM LIFE SCIENCES, P.U.L.S. AB (SE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310451-A1 | TRICYCLIC LACTONES FOR TREATMENT OF CANCER | STAT3, IL6, STAT6 | SLC6A3 4792/4885ALDH1A1 3026/4885KDM4E 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.